A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma

Ottawa Hospital Research Institute20 enrolled

Overview

The purpose of this project is to assess the feasibility of collecting plasma samples for cardiac biomarker assessment, and to identify if there is an associations between the biomarkers, echocardiographic features and the cardiac PET scan results (in patients receiving radiation therapy). This is the first step in a research program that has an overall goal of being able to predict early-treatment induced cardiotoxicity in patients with breast cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Feasibility studyOTHER

All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.

Eligibility

Sex: FEMALEMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Stage I-III, HER2-neu positive invasive ductal carcinoma 2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-D) chemotherapy 3. Scheduled to receive adjuvant Trastuzumab 4. ECOG Performance status 0-2 5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of ≥ 55%. Additionally, breast cancer patients≥45 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans. Exclusion Criteria: 1. Prior anthracycline chemotherapy 2. History of dilated cardiomyopathy, congestive heart failure, or coronary artery disease 3. Life expectancy less than 15 months 4. Pregnant or lactating women 5. Use of beta receptor antagonists, calcium channel antagonists, angiotensin converting enzyme inhibitors, or angiotensin receptor inhibitors at baseline. 6. Previous chest wall/breast or nodal radiation.

Locations (1)

The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

Recruitment rates

Time frame: every 4 weeks up to 2 years

Secondary Outcomes

Cardiotoxicity

To measure biomarkers, myocardial perfusion, cardiac adverse events and peak systolic longitudinal strain.

Time frame: Once when the last participant completes week 57

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.